MDS pays a premium for Molecular Devices buyout

Analysts say MDS' deal to buy Molecular Devices for $615 million represents a "healthy premium" for investors. MDS plans to combine Sunnyvale, CA-based Molecular Devices, which makes software and systems for researchers engaged in biochemical testing and cellular analysis, with MDS Sciex into a unit with 1,100 employees. The unit will be led by Andy Boorn. MDS is paying $35.50 a share, a 49 percent premium over the January 26 closing price. MDS says that the FDA is close to wrapping up a long and expensive review of its research centers after the agency cited the company for failing to fix the sources of contamination found in blood tests.

- check out the release on the buyout
- here's the report from the Toronto Star
- and the report from the San Jose Mercury News

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.